Arne Freundt, CEO of PUMA, said he was “pleased” with the company’s “solid sales growth.” He added, “We made significant ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...

and marketing strategies for the first time for our Speedcat which shows promising sales numbers in its current go-to-market phase before scaling up this summer. All these important achievements in ...

Interim data from this study is expected to be announced later in 2025. Puma Biotechnology initiated the phase II ALISCA-Breast1 study on alisertib in combination with endocrine treatment for ...

In addition, Puma currently has two ongoing Phase 2 trials of our investigational drug alisertib. The first is the ALISCA-Breast1, which is a Phase 2 of alisertib in combination with endocrine ...

In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024 ...

In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024 ...